Category Archives

5 Articles

One-dose Human Papillomavirus (HPV) vaccine

It is with pleasure that we received recently the new HPV vaccination strategy from the WHO:

One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer

The 4-7 April convening of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) evaluated the evidence that has been emerging over past years that single-dose schedules provide comparable efficacy to the two or three-dose regimens.

SAGE’s review concluded that a single-dose Human Papillomavirus (HPV)vaccine delivers solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules.  This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls.

Often referred to as the ‘silent killer’ and almost entirely preventable, cervical cancer is a disease of inequity of access; the new SAGE recommendation is underpinned by concerns over the slow introduction of the HPV vaccine into immunization programs and overall low population coverage, especially in poorer countries.

More than 95% of cervical cancer is caused by sexually transmitted HPV, which is the fourth most common type of cancer in women globally with 90% of these women living in low- and middle-income countries. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.”

SAGE recommends updating dose schedules for HPV as follows:

one or two-dose schedule for the primary target of girls aged 9-14

one or two-dose schedule for young women aged 15-2O

two doses with a 6-month interval for women older than 21.

Immunocompromised individuals, including those with HIV, should receive three doses if feasible, and if not at least two doses. There is limited evidence regarding the efficacy of a single dose in this group.

The option for a single dose of the vaccine is less costly, less resource intensive and easier to administer. It facilitates implementing catch-up campaigns for multiple age groups, reduces the challenges link ed to tracing girls for their second dose and allows for financial and human resources to be redirected to other health priorities.”

Women with Bleeding Disorders | Micro E-Learning

Women with Bleeding Disorders | Micro E-Learning

by EURAPAG

Many healthcare professionals, including general practitioners, obstetricians and gynaecologists, can play a crucial role in reducing the time to diagnosis of bleeding disorders in women and girls. A multidisciplinary team of experts have developed an accredited micro e-learning programme to increase awareness, knowledge, and understanding of bleeding disorders and their management among healthcare professionals who are the first to see signs and symptoms of bleeding disorders in women and girls.

The programme consists of two short modules. Within each module there is a 2-minute animation video, a downloadable slide set and a flashcard.

Go to
https://www.hemostasisconnect.info 
to access the materials.


The programme has been developed by the following multidisciplinary team of experts:

Prof. Rezan Abdul-Kadir, Obstetrician and Gynaecologist, The Royal Free Foundation Hospital, London, UK
Dr Sarah O’Brien, Paediatric Haematologist, Nationwide Children’s Hospital, Columbus, OH, USA
Dr Karin van Galen, Haematologist, Van Creveldkliniek, UMC Utrecht, Netherland
Dr Michelle Lavin, Haematologist, National Coagulation Centre, St James’ Hospital, Dublin, Ireland
Dr Roseline d’Oiron, Haematologist, Reference Centre for Haemophilia and RBD, Bicêtre Hospital AP-HP and University of Paris-Saclay, Le Kremlin-Bicêtre, France
Debra Pollard, Lead Nurse, Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK

PROF. JAN HOŘEJŠÍ †



horejsibwrahmen

PROF. JAN HOŘEJŠÍ
May 6th, 1940 – November 18th, 2016

On November 18th, 2016, Prof. Jan Horejsi passed away.

Born in Prague, the homeland of Pediatric and Adolescent Gynecology, when Prof. Peter launched his practice, Prof. Horejsi gave a great contribution to our discipline, mainly dealing with genital anomalies.

Former director of the Dept. of Obstetrics and Adult and Pediatric Gynecology at the Charles University of Prague and treasurer of FIGIJ for more than 20 years, he was the main sponsor, founder and first president of EURAPAG, of which he was an active member till the end of his life with the office of Honorary President.

But, mainly, he was a friend of all of us.

Heartfelt Sympathies to his wife, children and grandchildren
from all EURAPAG Board Members.